A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors. Conference Paper uri icon

authors

  • Desai, Jayesh
  • Markman, Ben
  • Sandhu, Shahneen Kaur
  • Gan, Hui Kong
  • Friedlander, Michael
  • Tran, Ben
  • Meniawy, Tarek
  • Boolell, Vishal
  • Colyer, Duncan
  • Norris, Christie
  • Ameratunga, Malaka
  • Yang, Jason
  • Li, Kang
  • Wang, Lai
  • Luo, Lusong
  • Qin, Zhen
  • Millward, Michael

publication date

  • May 20, 2016